Institutional members access full text with Ovid®

Share this article on:

INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION WITH LARGE SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION

Iacono, Pierluigi MD*; Parodi, Maurizio B. MD; Introini, Ugo MD; La Spina, Carlo MD; Varano, Monica MD*; Bandello, Francesco MD

doi: 10.1097/IAE.0b013e3182979e33
Original Study

Purpose: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration.

Methods: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features.

Results: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 µm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 µm (P < 0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered.

Conclusion: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

*G. B. Bietti Foundation for Ophthalmology, Scientific Institute of Admission and Care, Rome, Italy; and

Department of Ophthalmology, Vita-Salute San Raffaele University, Milan, Italy.

Reprint requests: Pierluigi Iacono, MD, G. B. Bietti Foundation for Ophthalmology, Scientific Institute of Admission and Care, Via Livenza 3, 00198 Rome, Italy; e-mail: pierluigi.iacono@libero.it

F. Bandello is an Advisory Board member for Novartis Pharma. The other authors have no financial/conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.